Thymosin Alpha-1 — Vendor Pricing & Purity Guide
Research Overview
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland. It plays a central role in T-cell maturation and immune system regulation. The synthetic version, marketed as Zadaxin, is approved in over 35 countries for treatment of hepatitis B, hepatitis C, and as an immune system adjuvant. While not FDA-approved in the United States, it has one of the broadest international approval profiles of any peptide therapeutic.
Tα1 works by enhancing dendritic cell maturation, promoting T-cell differentiation (particularly CD4+ and CD8+ T-cells), and modulating cytokine production. It acts through Toll-like receptors TLR2 and TLR9, key components of the innate immune system that detect pathogens. This dual activation of both innate and adaptive immunity makes Tα1 one of the most broadly effective immunomodulatory peptides available.
Thymosin Alpha-1 gained renewed attention during the COVID-19 pandemic when retrospective studies in China showed improved outcomes in critically ill patients. Its ability to restore T-cell function in immunocompromised patients without causing the dangerous "cytokine storm" associated with other immune stimulants makes it particularly valuable in infectious disease and immunodeficiency research.
Key Research Findings
- •Approved in 35+ countries for hepatitis B, hepatitis C, and immune deficiency — one of the most widely approved peptide drugs globally
- •Improved survival and reduced need for mechanical ventilation in COVID-19 patients with lymphopenia in retrospective studies
- •Enhanced vaccine response rates in immunocompromised patients including elderly and cancer patients
- •Increased CD4+ and CD8+ T-cell counts in patients with chronic hepatitis B
- •Demonstrated anti-tumor activity as adjunctive therapy in melanoma, hepatocellular carcinoma, and lung cancer clinical trials
- •Modulated immune response without triggering cytokine storm — important safety distinction from other immune stimulants
Research Dosage Protocols
Thymosin Alpha-1 (Zadaxin) is administered as 1.6 mg subcutaneous injection twice weekly in approved clinical protocols for hepatitis B/C. This dosing schedule is based on extensive Phase III clinical trial data.
For research use, Tα1 is available as lyophilized powder reconstituted with sterile water. The standard research and clinical dose is 1.6 mg (1600 mcg) per injection.
Treatment courses typically run 6-12 months for chronic viral hepatitis. For immune enhancement research (vaccine adjuvant studies, cancer immunotherapy), shorter courses of 4-8 weeks have been studied.
For research reference only. Not medical advice. Not for human consumption.
Published Research (2 studies)
- [1]
- [2]
Links go to PubMed (NIH National Library of Medicine). PeptideVerdict is not affiliated with these studies.
Price Comparison (21 products from 12 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Paradigm Peptides | $40.00 $4.00/mg 10mg lyophilized | In Stock |
| Polaris Peptides | $65.00 $6.50/mg 10mg lyophilized | In Stock |
| Pure Rawz | $65.98 $6.60/mg 10mg vial | In Stock |
| Skye Peptides | $79.00 $7.90/mg 10mg lyophilized | In Stock |
| Simple Peptide | $86.00 $8.60/mg 10mg lyophilized | In Stock |
| Particle Peptides | $44.99 $9.00/mg 5mg lyophilized | In Stock |
| BioLongevity Labs | $129.97 $13.00/mg 10mg vial | In Stock |
| Peptide Sciences | $130.00 $13.00/mg 10mg lyophilized | In Stock |
| Biotech Peptides | $130.00 $13.00/mg 10mg vial | In Stock |
| Skye Peptides | $89.00 $14.83/mg 6mg lyophilized | In Stock |
| Core Peptides | $81.00 $16.20/mg 5mg vial | In Stock |
| Peptide Sciences | $50.00 $16.67/mg 3mg lyophilized | In Stock |
| BioLongevity Labs | $249.97 $499.94/mg 0.5mg vial | In Stock |
| Soma Chems | $49.99 vial | In Stock |
| Swiss Chems | $63.99 vial | In Stock |
| BioLongevity Labs | $104.00 vial | In Stock |
| BioLongevity Labs | $85.00 capsule | In Stock |
| BioLongevity Labs | $85.00 capsule | In Stock |
| BioLongevity Labs | $85.00 capsule | In Stock |
| BioLongevity Labs | $85.00 capsule | In Stock |
| BioLongevity Labs | $85.00 capsule | In Stock |
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino-acid immune-modulating peptide produced by the thymus gland. The synthetic version (Zadaxin) is approved in 35+ countries for hepatitis and immune deficiency. It enhances T-cell function and both innate and adaptive immunity.
Is Thymosin Alpha-1 FDA-approved?
No, it is not FDA-approved in the United States. However, it is approved in over 35 countries including China, Russia, India, and many others for hepatitis B, hepatitis C, and immune deficiency treatment.
How is Thymosin Alpha-1 different from TB-500?
Despite similar names, they are completely different peptides. Thymosin Alpha-1 (28 amino acids, from the thymus) modulates immune function. TB-500 (a fragment of Thymosin Beta-4, 43 amino acids) promotes tissue repair through actin regulation. Different source proteins, different mechanisms.
Where can I buy Thymosin Alpha-1 for research?
Thymosin Alpha-1 is available from research peptide vendors. Compare pricing in the table above.